XOMA (NASDAQ:XOMA) Releases Earnings Results

XOMA (NASDAQ:XOMA) announced its quarterly earnings data on Monday. The biotechnology company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17), Zacks reports. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The firm had revenue of $8.70 million during the quarter, compared to the consensus estimate of $8.75 million.

XOMA Price Performance

XOMA stock opened at $20.73 on Tuesday. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The company has a market capitalization of $244.26 million, a PE ratio of -5.96 and a beta of 1.00. XOMA has a one year low of $19.92 and a one year high of $35.00. The business has a 50 day simple moving average of $24.74 and a 200 day simple moving average of $27.35.

Insider Buying and Selling

In other XOMA news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of XOMA stock in a transaction on Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.20% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on XOMA. StockNews.com downgraded XOMA from a “hold” rating to a “sell” rating in a research report on Tuesday, February 25th. HC Wainwright reduced their price objective on XOMA from $123.00 to $104.00 and set a “buy” rating for the company in a research report on Monday, February 3rd.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.